Myeloma Paper of the Day, September 11th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Systematic review and meta-analysis of 5,517 lymphoma and myeloma patients post-CAR T finds overall SPM point estimate of 5.8%, but no differences in randomized studies vs. control arms (p=0.92)”

Source: Robert Orlowski/X

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Authors: Tobias Tix, Mohammad Alhomoud, Roni Shouval, Edward R Scheffer Cliff, Miguel-Angel Perales, David M Cordas Dos Santos, Kai Rejeski.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.